Clinical Trial Update: Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating XNW5004 in combination with enzalutamide for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• XNW5004
• Xtandi (enzalutamide)

Snippet

Sponsor: Evopoint Biosciences Inc. | Conditions: Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 1, Phase 2 | Status: RECRUITING